1. Home
  2. ATAI vs HURA Comparison

ATAI vs HURA Comparison

Compare ATAI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATAI
  • HURA
  • Stock Information
  • Founded
  • ATAI 2018
  • HURA 2009
  • Country
  • ATAI Germany
  • HURA United States
  • Employees
  • ATAI N/A
  • HURA N/A
  • Industry
  • ATAI Biotechnology: Pharmaceutical Preparations
  • HURA
  • Sector
  • ATAI Health Care
  • HURA
  • Exchange
  • ATAI Nasdaq
  • HURA Nasdaq
  • Market Cap
  • ATAI 214.8M
  • HURA 246.9M
  • IPO Year
  • ATAI 2021
  • HURA N/A
  • Fundamental
  • Price
  • ATAI $1.24
  • HURA $4.39
  • Analyst Decision
  • ATAI Strong Buy
  • HURA
  • Analyst Count
  • ATAI 4
  • HURA 0
  • Target Price
  • ATAI $9.00
  • HURA N/A
  • AVG Volume (30 Days)
  • ATAI 1.3M
  • HURA 668.3K
  • Earning Date
  • ATAI 11-13-2024
  • HURA 02-15-2025
  • Dividend Yield
  • ATAI N/A
  • HURA N/A
  • EPS Growth
  • ATAI N/A
  • HURA N/A
  • EPS
  • ATAI N/A
  • HURA N/A
  • Revenue
  • ATAI $331,000.00
  • HURA N/A
  • Revenue This Year
  • ATAI $93.15
  • HURA N/A
  • Revenue Next Year
  • ATAI N/A
  • HURA N/A
  • P/E Ratio
  • ATAI N/A
  • HURA N/A
  • Revenue Growth
  • ATAI N/A
  • HURA N/A
  • 52 Week Low
  • ATAI $1.03
  • HURA $2.84
  • 52 Week High
  • ATAI $2.85
  • HURA $14.60
  • Technical
  • Relative Strength Index (RSI)
  • ATAI 33.95
  • HURA N/A
  • Support Level
  • ATAI $1.15
  • HURA N/A
  • Resistance Level
  • ATAI $1.69
  • HURA N/A
  • Average True Range (ATR)
  • ATAI 0.11
  • HURA 0.00
  • MACD
  • ATAI -0.06
  • HURA 0.00
  • Stochastic Oscillator
  • ATAI 3.69
  • HURA 0.00

About ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: